03.05.12
Roche has signed a manufacturing contract with India-based Emcure Pharmaceuticals for its anti-cancer biologics Herceptin and MabThera, as reported by The Economic Times. Emcure will manufacture Herceptin and MabThera for the Indian market and based on the success, may be marketed in other developing countries. These drugs are currently under process development and are expected to be available by 2013.
“This deal will equip Emcure to manufacture products that are sophisticated monoclonal antibodies. We look at this as Emcure’s first project with Roche,” said Mukund Ranade, director, Emcure Pharmaceuticals. “Depending on the success, we hope cooperation will become broad based”
This agreement represents Roche’s first manufacturing contract in India, which may be part of an effort to thwart generic substitutes of its drugs in the region.
“This deal will equip Emcure to manufacture products that are sophisticated monoclonal antibodies. We look at this as Emcure’s first project with Roche,” said Mukund Ranade, director, Emcure Pharmaceuticals. “Depending on the success, we hope cooperation will become broad based”
This agreement represents Roche’s first manufacturing contract in India, which may be part of an effort to thwart generic substitutes of its drugs in the region.